---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-005253"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T10:52:22.223319+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palatin reports positive initial Phase 3 data for PL9643 dry eye drug at ARVO

## Summary
- PL9643 showed statistically significant improvement on multiple sign and symptom endpoints in Phase 2 and Phase 3 lead-in data.
- No ocular adverse events or discontinuations due to tolerability; excellent safety profile.
- MELODY-1 Phase 3 study continues; topline data expected in second half of 2023.
- Data presented at ARVO 2023; magnitude of difference vs vehicle exceeds reported for approved products for several endpoints.

## SEC filing metadata
- accession: 0001654954-23-005253
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423005253/0001654954-23-005253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423005253/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-005253
- JSON: https://secwatch.observer/filing/0001654954-23-005253.json
- Plain text: https://secwatch.observer/filing/0001654954-23-005253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.